Testing a New COVID-19 Drug for Mild to Moderate Cases
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have tested positive for COVID-19 in the last 5 days (120 hours).
- Your COVID-19 symptoms must have started within the last 5 days.
- You must have at least one symptom (like fever, cough, or body aches) in the last 24 hours.
- You cannot have needed hospital care or oxygen therapy for your COVID-19.
- You must not have any serious liver or kidney problems or a weakened immune system.
- You cannot have received a COVID-19 vaccine in the last 4 months or plan to during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This study tests an experimental oral antiviral, secutrelvir, for people with mild to moderate COVID-19 who are not sick enough to need hospital care. The medicine aims to reduce symptoms and help you recover faster.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This trial tests whether giving remdesivir to kidney transplant patients who test positive for COVID-19 can prevent them from getting severely ill. It is for people who have already had at least three COVID-19 vaccine doses and are scheduled to receive a kidney transplant soon.
This trial tests a longer course of remdesivir plus Paxlovid (nirmatrelvir/ritonavir) for immunocompromised people with persistent COVID-19. It aims to see if combining these two antiviral medicines can help clear the virus more effectively.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.